Large Consortium Study Reveals More Details on the Link Between Viruses and Cancer
Researchers use whole-genome and whole-transcriptome sequencing data to reveal viral sequences in cancer tissue.
Kidney Cancer
Can Researchers Harness Metabolic Changes in Renal Cell Carcinoma to Improve Prognosis?
Many individual metabolite changes are often common among cancers and not specific to RCC, making the identification of diagnostic or prognostic biomarkers difficult.
Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real-World Setting
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Preoperative Bone Metastases Not Prognostic in mRCC
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Intermediate-Risk mRCC Patients Have Heterogeneous Survival Outcomes
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
Metastasectomy Found to Prolong Survival in Selected mRCC Cases
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
CN for mRCC Does Not Up Survival in the Immune Checkpoint Inhibitor Era
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Risky Business: A New Scoring System for Metastatic Renal Cell Carcinoma
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Next post in Renal Cell Carcinoma
